Elena Muraro, Barbara Montico, Benedict Lum, Francesca Colizzi, Giorgio Giurato, Annamaria Salvati, Roberto Guerrieri, Aurora Rizzo, Elisa Comaro, Vincenzo Canzonieri, Andrea Anichini, Michele Del Vecchio, Roberta Mortarini, Massimo Milione, Alessandro Weisz, Maria Antonietta Pizzichetta, Fiona Simpson, Riccardo Dolcetti, Elisabetta Fratta, Luca Sigalotti
INTRODUCTION: About 50% of cutaneous melanoma (CM) patients present activating BRAF mutations that can be effectively targeted by BRAF inhibitors (BRAFi). However, 20% of CM patients exhibit intrinsic drug resistance to BRAFi, while most of the others develop adaptive resistance over time. The mechanisms involved in BRAFi resistance are disparate and globally seem to rewire the cellular signaling profile by up-regulating different receptor tyrosine kinases (RTKs), such as the epidermal growth factor receptor (EGFR)...
2024: Frontiers in Immunology